Effect of a new sulfa-trimethoprim combination (trimethoprim-sulfamethopyrazine) in typhoid fever. A double-blind study on 72 adult patients.

Abstract

A double-blind study on 72 adult patients affected by typhoid fever was done utilizing a new sulfa-trimethoprim combination (trimethoprim-sulfamethopyrazine) versus the well-known combination trimethoprim-sulfamethoxazole. The dosage used for the new drug was 2 capsules (250 mg trimethoprim + 200 mg sulfamethopyrazine per capsule) the 1st day and 1 capsule for the following 14 days or 2 capsules (trimethoprim 80 mg + sulfamethoxazole 400 mg per capsule) twice daily for 15 days. Both drugs proved to be very effective according to the parameters considered. No complications (intestinal bleeding, perforation, etc.) occurred in any of the patients, and untoward effects were not observed. It is therefore our opinion that treatment of typhoid fever with a sulfa-trimethoprim combination is both effective and safe.

• Authors: O Schiraldi, E Sforza, F Piaia
• Journal: Chemotherapy (Chemotherapy) Vol. 31 Issue 1 Pg. 68-75 ( 1985) ISSN: 0009-3157 [Print] Switzerland
• PMID: 3882355 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Drug Combinations
• Sulfanilamides
• Trimethoprim, Sulfamethoxazole Drug Combination
• Trimethoprim
• Sulfamethoxazole
• Sulfalene

Topics

• Adolescent
• Adult
• Clinical Trials as Topic
• Double-Blind Method
• Drug Combinations (therapeutic use)
• Female
• Humans
• Male
• Random Allocation
• Sulfalene (administration & dosage, therapeutic use)
• Sulfamethoxazole (therapeutic use)
• Sulfanilamides (therapeutic use)
• Trimethoprim (administration & dosage, therapeutic use)
• Trimethoprim, Sulfamethoxazole Drug Combination
• Typhoid Fever (drug therapy)